1.76
price up icon0.00%   0.00
after-market Handel nachbörslich: 1.76
loading

Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten

pulisher
05:10 AM

How The Coherus Oncology (CHRS) Narrative Is Evolving Around Clinical Catalysts And Valuation Risks - Yahoo Finance

05:10 AM
pulisher
Mar 04, 2026

Coherus BioSciences at TD Cowen Conference: Strategic Oncology Shift - Investing.com

Mar 04, 2026
pulisher
Mar 04, 2026

CHRS: Strong oncology focus, robust pipeline, and accelerating LOQTORZI sales drive future growth - TradingView

Mar 04, 2026
pulisher
Mar 04, 2026

CHRS: Rapid oncology transformation, strong LOQTORZI growth, and promising pipeline assets drive outlook - TradingView

Mar 04, 2026
pulisher
Mar 02, 2026

Coherus Oncology, Inc. to Release 2025 Financial Results on March 9, 2026, with Conference Call to Follow - Quiver Quantitative

Mar 02, 2026
pulisher
Mar 02, 2026

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026 - GlobeNewswire

Mar 02, 2026
pulisher
Mar 02, 2026

Coherus Oncology (CHRS) Projected to Post Quarterly Earnings on Monday - MarketBeat

Mar 02, 2026
pulisher
Mar 01, 2026

CHRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 01, 2026
pulisher
Feb 26, 2026

Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget

Feb 26, 2026
pulisher
Feb 25, 2026

Hepatocellular Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 90+ Key Companies | DelveInsight - StreetInsider

Feb 25, 2026
pulisher
Feb 25, 2026

Hepatocellular Carcinoma Clinical Trial Pipeline Shows - openPR.com

Feb 25, 2026
pulisher
Feb 24, 2026

Coherus Oncology (NASDAQ:CHRS) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat

Feb 24, 2026
pulisher
Feb 23, 2026

Coherus Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire

Feb 23, 2026
pulisher
Feb 20, 2026

Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114 (NASDAQ:CHRS) - Seeking Alpha

Feb 20, 2026
pulisher
Feb 19, 2026

Coherus Oncology announces proposed public offering of common stock - MSN

Feb 19, 2026
pulisher
Feb 18, 2026

How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) - Yahoo Finance

Feb 18, 2026
pulisher
Feb 18, 2026

Coherus closes $50.1 million public offering of common stock By Investing.com - Investing.com Australia

Feb 18, 2026
pulisher
Feb 17, 2026

Coherus closes $50.1 million public offering of common stock - Investing.com India

Feb 17, 2026
pulisher
Feb 17, 2026

Coherus Biosciences Completes $47 Million Equity Offering - TipRanks

Feb 17, 2026
pulisher
Feb 17, 2026

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock - The Manila Times

Feb 17, 2026
pulisher
Feb 17, 2026

Oncology biotech Coherus raises $50M for LOQTORZI and clinical programs - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

Coherus Oncology (NASDAQ: CHRS) raises $47M through common stock offering - Stock Titan

Feb 17, 2026
pulisher
Feb 17, 2026

More drugmakers are turning to cancer combos. Will it help patients live longer? - PharmaVoice

Feb 17, 2026
pulisher
Feb 16, 2026

Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of "Hold" by Analysts - MarketBeat

Feb 16, 2026
pulisher
Feb 14, 2026

Coherus Oncology prices $50.1 million public offering of common stock By Investing.com - Investing.com Canada

Feb 14, 2026
pulisher
Feb 14, 2026

Coherus BioSciences stock falls after pricing $50.1 million share offering By Investing.com - Investing.com Australia

Feb 14, 2026
pulisher
Feb 14, 2026

CHRS Should I Buy - Intellectia AI

Feb 14, 2026
pulisher
Feb 13, 2026

CHRS Successfully Completes Joint Book-Running Offering - GuruFocus

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Oncology prices stock offering to raise $50.1M - MSN

Feb 13, 2026
pulisher
Feb 13, 2026

Latham & Watkins Advises Coherus Oncology on Public Offering of Common Stock - Latham & Watkins LLP

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Oncology’s Stock Offering: Strategic Moves Unveiled - timothysykes.com

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus BioSciences stock falls after pricing $50.1 million share offering - Investing.com

Feb 13, 2026
pulisher
Feb 13, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Oncology tumbles on $50 mln stock sale - TradingView

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Prices $50.1 Mln Public Offering; Stock Plunges - RTTNews

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Oncology (CHRS) Launches $50.1M Public Offering - GuruFocus

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus BioSciences Prices $50.1 Million Share Offering - marketscreener.com

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus BioSciences (CHRS) Announces Public Stock Offering - GuruFocus

Feb 13, 2026
pulisher
Feb 13, 2026

Coherus Oncology prices $50.1 million public offering of common stock - Investing.com

Feb 13, 2026
pulisher
Feb 12, 2026

Coherus Oncology Prices Public Offering at $1.75 per Share - Intellectia AI

Feb 12, 2026
pulisher
Feb 12, 2026

Cancer-drug firm Coherus to raise $50M for LOQTORZI, clinical development - Stock Titan

Feb 12, 2026
pulisher
Feb 12, 2026

Coherus Oncology announces pricing of public offering of common stock - marketscreener.com

Feb 12, 2026
pulisher
Feb 12, 2026

Coherus Oncology Announces Pricing Of Public Offering Of Common Stock - TradingView

Feb 12, 2026
pulisher
Feb 12, 2026

Press Release: Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock - 富途牛牛

Feb 12, 2026
pulisher
Feb 12, 2026

Coherus Oncology tumbles on planned equity offering - TradingView

Feb 12, 2026
pulisher
Feb 12, 2026

Coherus Oncology, Inc. Announces Proposed Public Offering of Common Stock - The Manila Times

Feb 12, 2026
$45.68
price down icon 3.69%
$53.83
price down icon 6.87%
$29.72
price up icon 0.68%
$101.95
price down icon 1.78%
$143.54
price down icon 4.23%
biotechnology ONC
$292.94
price down icon 2.03%
Kapitalisierung:     |  Volumen (24h):